| Name | Leminoprazole |
| Description | Leminoprazole is an orally available H+,K(+)-ATPase inhibitor that protects gastric mucosal cells from various cellular damages. |
| In vitro | Leminoprazole, when given orally at doses of 10-100 mg/kg, was able to dose-dependently inhibit H+, K(+)-ATPase activity at 3 and 6 hours after administration. Specifically, Leminoprazole (60 mg/kg, p.o.) inhibited H+, K(+)-ATPase for a much longer duration than omeprazole (30 mg/kg, p.o.). In pylorus ligated rats, the inhibitory effect of Leminoprazole on gastric acid secretion and its inhibitory rate on H+, K(+)-ATPase activity showed a good correlation, suggesting that the inhibitory efficacy of Leminoprazole in inhibiting gastric acid secretion via H+, K(+)-ATPase activity is comparable to that of omeprazole. The inhibitory effect was comparable to that of omeprazole. In addition, Leminoprazole (100 mg/kg) directly inhibited H+, K(+)-ATPase activity even when administered intragastrically after pyloric ligation, demonstrating the ability of this compound to inhibit H+, K(+)-ATPase activity directly from the gastric lumen. Further studies showed that continuous administration of Leminoprazole (100 mg/kg, p.o.) for 2 or 4 weeks had the same inhibitory effect on H+, K(+)-ATPase as a single dose. |
| In vivo | Leminoprazole, when given orally at doses of 10-100 mg/kg, was able to dose-dependently inhibit H+, K(+)-ATPase activity at 3 and 6 hours after administration. Specifically, Leminoprazole (60 mg/kg, p.o.) inhibited H+, K(+)-ATPase for a much longer duration than omeprazole (30 mg/kg, p.o.). In pylorus ligated rats, the inhibitory effect of Leminoprazole on gastric acid secretion and its inhibitory rate on H+, K(+)-ATPase activity showed a good correlation, suggesting that the inhibitory efficacy of Leminoprazole in inhibiting gastric acid secretion via H+, K(+)-ATPase activity is comparable to that of omeprazole. The inhibitory effect was comparable to that of omeprazole. In addition, Leminoprazole (100 mg/kg) directly inhibited H+, K(+)-ATPase activity even when administered intragastrically after pyloric ligation, demonstrating the ability of this compound to inhibit H+, K(+)-ATPase activity directly from the gastric lumen. Further studies showed that continuous administration of Leminoprazole (100 mg/kg, p.o.) for 2 or 4 weeks had the same inhibitory effect on H+, K(+)-ATPase as a single dose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (146.43 mM)
|
| Keywords | Leminoprazole |
| Inhibitors Related | Tirofiban hydrochloride monohydrate | Sodium oleate | trans-Aconitic acid | Phlorizin | Chlorpropamide | Vonoprazan fumarate | Revaprazan hydrochloride | Oleic acid | Esomeprazole Sodium | Trichlormethiazide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max |
United States
